Clinical trial
Atorvastatin For The Reduction Of Ventricular Arrhythmias
NCT00457340 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00457340 |
|---|---|
| Title | Atorvastatin For The Reduction Of Ventricular Arrhythmias |
| Official title | Cholesterol Lowering and Arrhythmia Recurrences After Internal Defibrillator Implantation (CLARIDI) |
| Acronym | CLARIDI |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Arrhythmia |
| Intervention type | Drug |
| Interventions | Atorvastatin 80mg |
| Enrollment | 220 |
| Start date | Feb 1, 2000 |
| Completion | Sep 1, 2004 |
| First posted | Apr 6, 2007 |
| Last update posted | Feb 18, 2021 |
| Countries | Belgium, Greece |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: